CORT LAWSUIT ALERT: Levi & Korsinsky Notifies Corcept Therapeutics Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud related to misleading statements about the FDA's feedback on the company's drug relacorilant [1]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between October 31, 2024, and December 30, 2025 [1]. - The complaint claims that Corcept Therapeutics made false statements regarding their interactions with the FDA and the approval prospects of the relacorilant NDA [1]. - The FDA had expressed concerns about the adequacy of the program assessing relacorilant's effectiveness, which was not disclosed by the company [1]. Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until April 21, 2026, to request appointment as lead plaintiff [1]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [1]. - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [1].